Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
出版年份 2023 全文链接
标题
Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
作者
关键词
-
出版物
Frontiers in Immunology
Volume 14, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2023-01-18
DOI
10.3389/fimmu.2023.1109292
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer
- (2022) Bangyou Zuo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- 65P A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers
- (2022) H. Li ANNALS OF ONCOLOGY
- Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial
- (2021) Angela Lamarca et al. LANCET ONCOLOGY
- Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer
- (2021) José J. G. Marin et al. BRITISH JOURNAL OF CANCER
- Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.
- (2021) Zhou Jian et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination strategies to maximize the benefits of cancer immunotherapy
- (2021) Shaoming Zhu et al. Journal of Hematology & Oncology
- Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
- (2020) Kaichao Feng et al. Journal for ImmunoTherapy of Cancer
- Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
- (2020) Jianzhen Lin et al. Hepatobiliary Surgery and Nutrition
- Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline
- (2019) Rachna T. Shroff et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
- (2019) Makoto Ueno et al. Lancet Gastroenterology & Hepatology
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
- (2019) Andrew A. Davis et al. Journal for ImmunoTherapy of Cancer
- Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018
- (2018) Lorenzo Galluzzi et al. CELL DEATH AND DIFFERENTIATION
- Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
- (2018) Shetal A. Patel et al. IMMUNITY
- PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma
- (2018) Josine Quispel-Janssen et al. Journal of Thoracic Oncology
- A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma
- (2018) Weijing Sun et al. CANCER
- Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application
- (2018) Nancy Tray et al. Cancer Immunology Research
- Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
- (2016) J. W. Valle et al. ANNALS OF ONCOLOGY
- RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group
- (2016) Lawrence H. Schwartz et al. EUROPEAN JOURNAL OF CANCER
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2
- (2011) Apostolos C. Ziogas et al. INTERNATIONAL JOURNAL OF CANCER
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
- (2010) Juan Valle et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cutting Edge: Vascular Endothelial Growth Factor-Mediated Signaling in Human CD45RO+ CD4+ T Cells Promotes Akt and ERK Activation and Costimulates IFN- Production
- (2009) A. Basu et al. JOURNAL OF IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now